Concerning FD manifestations, patients with LVH also had greater plasma levels of the inflammatory mediators, like TNF, IL-6, and MMP-2, and patients with late gadolinium enhancement (marker of myocardial fibrosis) revealed higher plasma levels of MMP-2, mid-regional pro-atrial natriuretic peptide (MR-proANP), and B-type natriuretic peptide (BNP) [56] (Figure 3). The gene discussed is NR3C2; the disease is Fabry disease.